Literature DB >> 17440187

Risks and benefits of biologic therapy for inflammatory bowel diseases.

Geert D'Haens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17440187      PMCID： PMC1942157          DOI： 10.1136/gut.2006.103564

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  38 in total

Review 1.  Biologics in inflammatory bowel disease: how much progress have we made?

Authors:  W J Sandborn; W A Faubion
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Infliximab and reactivation of cerebral toxoplasmosis.

Authors:  Jeremy D Young; Bradford S McGwire
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

3.  Sargramostim for active Crohn's disease.

Authors:  Joshua R Korzenik; Brian K Dieckgraefe; John F Valentine; Diana F Hausman; Mark J Gilbert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

4.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

5.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Authors:  Annette Langer-Gould; Scott W Atlas; Ari J Green; Andrew W Bollen; Daniel Pelletier
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

6.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 7.  Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis.

Authors:  Keertan Dheda; Zarir F Udwadia; Jim F Huggett; Margaret A Johnson; Graham A W Rook
Journal:  Curr Opin Pulm Med       Date:  2005-05       Impact factor: 3.155

8.  Bias in analytic research.

Authors:  D L Sackett
Journal:  J Chronic Dis       Date:  1979

Review 9.  Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.

Authors:  U Mahadevan; S Kane; W J Sandborn; R D Cohen; K Hanson; J P Terdiman; D G Binion
Journal:  Aliment Pharmacol Ther       Date:  2005-03-15       Impact factor: 8.171

10.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864
View more
  20 in total

Review 1.  Top-down therapy for IBD: rationale and requisite evidence.

Authors:  Geert R D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

Review 2.  Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Authors:  Paweł Moćko; Paweł Kawalec; Andrzej Pilc
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

3.  Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.

Authors:  Christopher V Almario; Michelle S Keller; Michelle Chen; Karen Lasch; Lyann Ursos; Julia Shklovskaya; Gil Y Melmed; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 5.  Optimizing the safety of biologic therapy for IBD.

Authors:  Shanika de Silva; Shane Devlin; Remo Panaccione
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

6.  Same Day Infusion of Iron Therapy Is Associated With No Increased Risk for Adverse Events Among Patients Receiving Biological Infusions for Inflammatory Bowel Disease.

Authors:  Sumana Reddy; Brandon Shore; Lior Abramson; Hans H Herfarth; Edward L Barnes
Journal:  J Clin Gastroenterol       Date:  2022-07-22       Impact factor: 3.174

7.  Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.

Authors:  Angelica Nocerino; Alexandra Feathers; Elena Ivanina; Laura Durbin; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 8.  Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

Authors:  Shehzad A Saeed; Wallace V Crandall
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Sam68 contributes to intestinal inflammation in experimental and human colitis.

Authors:  Wendy A Goodman; Shrikanth C Basavarajappa; Angela R Liu; Franklin D Staback Rodriguez; Tailor Mathes; Parameswaran Ramakrishnan
Journal:  Cell Mol Life Sci       Date:  2021-10-24       Impact factor: 9.207

10.  Non-autophagy Role of Atg5 and NBR1 in Unconventional Secretion of IL-12 Prevents Gut Dysbiosis and Inflammation.

Authors:  Seth D Merkley; Samuel M Goodfellow; Yan Guo; Zoe E R Wilton; Janie R Byrum; Kurt C Schwalm; Darrell L Dinwiddie; Rama R Gullapalli; Vojo Deretic; Anthony Jimenez Hernandez; Steven B Bradfute; Julie G In; Eliseo F Castillo
Journal:  J Crohns Colitis       Date:  2022-02-23       Impact factor: 10.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.